• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688026.SS
Share

Guangzhou Jet Bio-Filtration Co., Ltd. Stocks

CN¥ 14.38Last Updated 15.07.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

CN¥ 284.37M

CN¥ 14.38
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Guangzhou Jet Bio-Filtration Co., Ltd. specializes in the research, development, manufacturing, and global distribution of a diverse range of laboratory products. Their extensive catalog features essential lab consumables like pipettes, tissue culture products, centrifuge tubes, and filtration items, alongside scientific instruments such as analyzers, various lab equipment, reagents, and gloves. The company's reach extends to approximately 50 countries worldwide, serving significant markets including the United States, Japan, Canada, Germany, Australia, and South Korea. Established in 2001, its headquarters are located in Guangzhou, China.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, overpriced on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 18:04

Wholesale prices in the U.S. fell in June—a development the market did not expect

15.07.2026 17:30

Assets under management at BlackRock exceeded $15 trillion for the first time

15.07.2026 17:00

OpenAI's first device will be a "smart speaker." Will this create competition for Apple?

15.07.2026 16:35

The stock price of Stride, a small edtech company, has plummeted. The reason is Anthropic

15.07.2026 16:00

"There Aren't Enough IT Budgets to Go Around": What Does IBM's Historic Plunge Mean for the Stock Market?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026